HC Wainwright Has Pessimistic View of AnaptysBio Q1 Earnings

AnaptysBio, Inc. (NASDAQ:ANAB) – Investment analysts at HC Wainwright reduced their Q1 2026 earnings estimates for AnaptysBio in a research report issued to clients and investors on Wednesday, March 4th. HC Wainwright analyst E. Bodnar now expects that the biotechnology company will post earnings per share of ($1.12) for the quarter, down from their prior estimate of ($1.02). HC Wainwright currently has a “Buy” rating and a $66.00 price target on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($6.08) per share. HC Wainwright also issued estimates for AnaptysBio’s Q2 2026 earnings at ($1.22) EPS, Q3 2026 earnings at ($1.51) EPS, Q4 2026 earnings at ($1.88) EPS, FY2026 earnings at ($6.52) EPS, FY2027 earnings at ($8.55) EPS, FY2028 earnings at ($3.51) EPS and FY2029 earnings at ($0.61) EPS.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Monday, March 9th. The biotechnology company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $0.89 by $0.69. The business had revenue of $108.25 million for the quarter, compared to the consensus estimate of $87.09 million. AnaptysBio had a negative net margin of 5.64% and a negative return on equity of 1,101.24%.

A number of other brokerages have also recently commented on ANAB. Guggenheim restated a “buy” rating on shares of AnaptysBio in a research report on Thursday, December 18th. Wedbush reissued an “outperform” rating and issued a $50.00 target price on shares of AnaptysBio in a report on Monday, November 24th. Stifel Nicolaus raised their target price on shares of AnaptysBio from $56.00 to $85.00 and gave the stock a “buy” rating in a research note on Thursday. UBS Group started coverage on shares of AnaptysBio in a research report on Wednesday, January 7th. They issued a “buy” rating and a $70.00 price target for the company. Finally, Barclays raised their price objective on shares of AnaptysBio from $78.00 to $79.00 and gave the company an “overweight” rating in a research report on Wednesday. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, AnaptysBio presently has an average rating of “Moderate Buy” and a consensus price target of $71.89.

AnaptysBio Price Performance

NASDAQ:ANAB opened at $57.28 on Friday. AnaptysBio has a one year low of $15.32 and a one year high of $63.47. The business has a fifty day moving average price of $50.17 and a 200-day moving average price of $38.78. The firm has a market capitalization of $1.65 billion, a price-to-earnings ratio of -110.15 and a beta of 0.32.

AnaptysBio declared that its board has authorized a share repurchase plan on Friday, November 21st that allows the company to repurchase $100.00 million in shares. This repurchase authorization allows the biotechnology company to purchase up to 9.6% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s board believes its stock is undervalued.

Insider Buying and Selling at AnaptysBio

In other news, Director Magda Marquet sold 11,000 shares of AnaptysBio stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $48.23, for a total transaction of $530,530.00. Following the sale, the director owned 9,930 shares in the company, valued at $478,923.90. This trade represents a 52.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Eric J. Loumeau sold 10,000 shares of the business’s stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $54.00, for a total transaction of $540,000.00. Following the completion of the transaction, the insider directly owned 12,835 shares in the company, valued at $693,090. This trade represents a 43.79% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 156,280 shares of company stock worth $7,254,939. Insiders own 33.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ANAB. Smartleaf Asset Management LLC increased its holdings in shares of AnaptysBio by 5,864.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 821 shares during the last quarter. Larson Financial Group LLC grew its holdings in AnaptysBio by 54.6% during the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 473 shares in the last quarter. Bessemer Group Inc. increased its stake in AnaptysBio by 950.0% in the 3rd quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 1,292 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of AnaptysBio by 175.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 1,377 shares in the last quarter. Finally, Osaic Holdings Inc. boosted its position in shares of AnaptysBio by 11,630.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 2,326 shares during the last quarter.

AnaptysBio News Summary

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: Stifel Nicolaus raised its price target to $85 and reiterated a Buy rating, signaling substantial upside vs. current levels. Stifel Nicolaus price-target raise
• Positive Sentiment: Barclays raised its target to $79 and moved to an Overweight rating, another institutional endorsement that supports upside expectations. Barclays price-target raise
• Positive Sentiment: H.C. Wainwright boosted its target to $66 and kept a Buy rating; the firm’s analyst also published a long?range FY2030 EPS projection (~$7.67), which is far above current consensus and implies strong optionality from AnaptysBio’s assets. H.C. Wainwright price-target raise HC Wainwright FY2030 note
• Neutral Sentiment: AnaptysBio announced a spin?off of its biopharma portfolio — a strategic move that can unlock value long term but often creates short?term uncertainty until details (timing, tax treatment, assets) are disclosed. Spin-off announcement
• Neutral Sentiment: Short?interest reports show a reported “large increase” but list zero shares and NaN changes — data appears inconsistent and likely not a meaningful signal. (Treat short?interest data as noisy/uncertain until clarified.)
• Negative Sentiment: Despite positive analyst action, intraday selling and higher-than-average volume suggest profit?taking or rotation away from a stock that recently traded near its 1?year high; that technical flow can drive near?term downside even with favorable analyst commentary.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.